The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Caris Life Sciences
Characterization of microsatellite instability (dMMR/MSI-H) and mutational landscape in a large contemporary cohort of upper tract urothelial cancer (UTUC) patients.
 
Arpit Rao
No Relationships to Disclose
 
Julie Elaine McGrath
Employment - Caris Life Sciences
 
Joanne Xiu
Employment - Caris Life Sciences
 
Andre Luiz De Souza
No Relationships to Disclose
 
Shuchi Gulati
Consulting or Advisory Role - Puma Biotechnology
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Conquer Cancer Foundation
 
Inas Abuali
No Relationships to Disclose
 
Smitha Sagaram
No Relationships to Disclose
 
Chadi Nabhan
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
W. Michael Korn
No Relationships to Disclose
 
Charles J. Ryan
Honoraria - Bayer; Janssen Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Clovis Oncology (Inst); Dendreon; Myovant Sciences; Roivant
Research Funding - Clovis Oncology (Inst); Genzyme (Inst)
 
Elisabeth I. Heath
Honoraria - Bayer; Dendreon; Sanofi; Seagen
Consulting or Advisory Role - Agensys; Bayer; Dendreon
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pharmacyclics (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Agensys; Bayer; Sanofi
Other Relationship - Caris Centers of Excellence